ICMJE DISCLOSURE FORM

Date: 26/08/2021
Your Name: Daniel F McAuley
Manuscript Title: **Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis (The EASI-SWITCH Trial).**
Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	NIHR HTA programme	This trial was funded by the NIHR HTA programme (reference 13/140/05)
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NIHR	Investigator in ARDS and COVID-19 studies
		Innovate UK	Investigator in ARDS and COVID-19 studies
		MRC	Investigator in ARDS studies including investigating MSCs
		Novavax	Investigator in COVID-19 vaccine study
		Northern Ireland HSC R&D division	Phase 2 REALIST study - Investigator led trial with MSCs in COVID-19

			Investigator in ARDS and COVID-19 studies
		Wellcome Trust	Investigator in ARDS and COVID-19 studies
3	Royalties or licenses	Queen's University Belfast	Patent for novel treatment for inflammatory disease (USB962032)
4	Consulting fees	Bayer	Consultancy for treatment of ARDS
		GlaxoSmithKline	Consultancy for treatments of ARDS
		Boehringer Ingelhelm	Consultancy for treatment of ARDS
		Novartis	Consultancy for treatment of COVID-19
		Eli Lilly	Consultancy for treatment of COVID-19
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Support for attending meetings and/or travel	GlaxoSmithKline	Educational seminar speaker
6	Payment for expert testimony Patents planned, issued or pending	____None	
7	Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board or Advisory Board	Vir Biotechnology, Inc	Member DSMB
		Faron Pharmaceuticals	Member DSMB
8	Patents planned, issued or pending Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	____None	
9	Participation on a Data Safety Monitoring Board or Advisory Board Stock or stock options	____None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical writing, gifts or other services	Intensive Care Society	Co-Director of research
		MRC / NIHR	Director of EME programme
			Member of the EME Strategy Advisory Committee Member of the EME Funding Committee member Member of the EME Funding Committee Remit & Comp Sub-Group. Former member of the NIHR/UKRI Covid-19 reviewing committee Former member of the HTA General committee and Commissioning committees.
11	Stock or stock options	____None	

	Other financial or non-financial interests		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	Insmed	Spouse has received consultancy fees for management of NTM pulmonary infection
		California Inst For Regenerative Medicine	Spouse has received payments for participation in grant review panel

Please place an "X" next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.